Racial response to angiotensin-converting enzyme therapy in systolic heart failure.

Daniel J. Dries, Clyde W. Yancy, Mark A. Strong, Mark H. Drazner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The treatment of heart failure with angiotensin-converting enzyme inhibitors has resulted in substantial improvements in morbidity and mortality due to heart failure. Varying reports in the literature have suggested that African Americans respond less well to angiotensin-converting enzyme inhibitors, but careful reanalysis of major clinical trials in heart failure, especially the Studies of Left Ventricular Dysfunction (SOLVD), demonstrates a similar mortality benefit for African Americans as for whites. Morbidity, measured as hospitalizations, may not be as favorably impacted. African Americans do respond to angiotensin-converting enzyme inhibitors as a preemptive strategy to prevent heart failure, but the incidence of heart failure is still higher in this population. Mechanisms for these potential nuances in the response to angiotensin-converting enzyme inhibitors are not yet clear. The exaggerated benefit of nitrates and hydralazine implicates alterations in nitric oxide homeostasis. Race is an inadequate model to explain the observed differences. Careful translational research focusing on genetic patterns of disease may help resolve these outstanding questions.

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalCongestive heart failure (Greenwich, Conn.)
Volume10
Issue number1
StatePublished - Jan 2004

Fingerprint

Systolic Heart Failure
Enzyme Therapy
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
African Americans
Morbidity
Hydralazine
Inborn Genetic Diseases
Translational Medical Research
Mortality
Left Ventricular Dysfunction
Treatment Failure
Nitrates
Nitric Oxide
Hospitalization
Homeostasis
Clinical Trials
Incidence
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Racial response to angiotensin-converting enzyme therapy in systolic heart failure. / Dries, Daniel J.; Yancy, Clyde W.; Strong, Mark A.; Drazner, Mark H.

In: Congestive heart failure (Greenwich, Conn.), Vol. 10, No. 1, 01.2004, p. 30-33.

Research output: Contribution to journalArticle

@article{c5a8a88ec52242dba09abb7966d89fe5,
title = "Racial response to angiotensin-converting enzyme therapy in systolic heart failure.",
abstract = "The treatment of heart failure with angiotensin-converting enzyme inhibitors has resulted in substantial improvements in morbidity and mortality due to heart failure. Varying reports in the literature have suggested that African Americans respond less well to angiotensin-converting enzyme inhibitors, but careful reanalysis of major clinical trials in heart failure, especially the Studies of Left Ventricular Dysfunction (SOLVD), demonstrates a similar mortality benefit for African Americans as for whites. Morbidity, measured as hospitalizations, may not be as favorably impacted. African Americans do respond to angiotensin-converting enzyme inhibitors as a preemptive strategy to prevent heart failure, but the incidence of heart failure is still higher in this population. Mechanisms for these potential nuances in the response to angiotensin-converting enzyme inhibitors are not yet clear. The exaggerated benefit of nitrates and hydralazine implicates alterations in nitric oxide homeostasis. Race is an inadequate model to explain the observed differences. Careful translational research focusing on genetic patterns of disease may help resolve these outstanding questions.",
author = "Dries, {Daniel J.} and Yancy, {Clyde W.} and Strong, {Mark A.} and Drazner, {Mark H.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "10",
pages = "30--33",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1527-5299",
publisher = "Le Jacq Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Racial response to angiotensin-converting enzyme therapy in systolic heart failure.

AU - Dries, Daniel J.

AU - Yancy, Clyde W.

AU - Strong, Mark A.

AU - Drazner, Mark H.

PY - 2004/1

Y1 - 2004/1

N2 - The treatment of heart failure with angiotensin-converting enzyme inhibitors has resulted in substantial improvements in morbidity and mortality due to heart failure. Varying reports in the literature have suggested that African Americans respond less well to angiotensin-converting enzyme inhibitors, but careful reanalysis of major clinical trials in heart failure, especially the Studies of Left Ventricular Dysfunction (SOLVD), demonstrates a similar mortality benefit for African Americans as for whites. Morbidity, measured as hospitalizations, may not be as favorably impacted. African Americans do respond to angiotensin-converting enzyme inhibitors as a preemptive strategy to prevent heart failure, but the incidence of heart failure is still higher in this population. Mechanisms for these potential nuances in the response to angiotensin-converting enzyme inhibitors are not yet clear. The exaggerated benefit of nitrates and hydralazine implicates alterations in nitric oxide homeostasis. Race is an inadequate model to explain the observed differences. Careful translational research focusing on genetic patterns of disease may help resolve these outstanding questions.

AB - The treatment of heart failure with angiotensin-converting enzyme inhibitors has resulted in substantial improvements in morbidity and mortality due to heart failure. Varying reports in the literature have suggested that African Americans respond less well to angiotensin-converting enzyme inhibitors, but careful reanalysis of major clinical trials in heart failure, especially the Studies of Left Ventricular Dysfunction (SOLVD), demonstrates a similar mortality benefit for African Americans as for whites. Morbidity, measured as hospitalizations, may not be as favorably impacted. African Americans do respond to angiotensin-converting enzyme inhibitors as a preemptive strategy to prevent heart failure, but the incidence of heart failure is still higher in this population. Mechanisms for these potential nuances in the response to angiotensin-converting enzyme inhibitors are not yet clear. The exaggerated benefit of nitrates and hydralazine implicates alterations in nitric oxide homeostasis. Race is an inadequate model to explain the observed differences. Careful translational research focusing on genetic patterns of disease may help resolve these outstanding questions.

UR - http://www.scopus.com/inward/record.url?scp=2142819309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142819309&partnerID=8YFLogxK

M3 - Article

C2 - 14872155

AN - SCOPUS:2142819309

VL - 10

SP - 30

EP - 33

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1527-5299

IS - 1

ER -